CClinicalTrials.gg
RecruitingNCT06420206Updated Jul 14, 2026

Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center

An interventional study of Standard of Care (Acute Cancer Care Center) and Standard of Care (Goals of Care) in Lung Cancer and Gastrointestinal Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Other

From the registry’s dates

  • Started May 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To improve quality of life for participants with advanced cancer, support their families, and lower overall cost of care.

Read the detailed description

Primary Objective:

To compare overall percentage of days spent in an acute care setting over the 30-day period from time of the index emergency department (ED), referred to as Acute Cancer Care Center (ACCC), visit for patients who receive the emergency department-based GOC intervention and those who do not.

Secondary Objective:

To obtain data on rates of admission to the ICU, death in the hospital setting, symptom improvement for participants hospitalized, hospice referral, survival, and 30-day care costs for participants who receive the GOC intervention in the ACCC and those who do not.

02

Conditions studied

  • Lung Cancer
  • Gastrointestinal Cancer
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's planned enrollment of 200 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Participant is at least 18 years old presenting to the triage area of the MDACC ACCC for treatment
  2. Participant has advanced lung or GI cancer. Advanced cancer patient defined as: locally recurrent or metastatic for which there is no curative treatment available.
  3. Participant screens positive for at least 2 of 3 triple threat conditions (dyspnea, altered mental status, or poor performance status)
  4. Participant has the ability to speak and write in English
  5. Participant has the ability to provide consent OR is accompanied by a LAR able to provide consent

Exclusion criteria

Exclusion Criteria:

  1. Participant is already enrolled in hospice
  2. Participant is comatose
  3. Participant has severe intellectual disability
  4. Participant has a history of dementia documented in the medical records
  5. Participant has baseline communication barriers such as aphasia or deafness
  6. Participant is new to MDACC, without established oncology care at our institution at time of ACCC arrival
  7. Participant is 18 years or older, currently cared for by pediatrics service
  8. Pregnant women
  9. Prisoners
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Acute Cancer Care Center

    In Group 1, participants will receive the usual standard of care, during your emergency room visit, provided by the Acute Cancer Care Center (ACCC) treating doctor who will address symptoms and other medical problems that brought the participant to the emergency room.

    Other: Standard of Care (Acute Cancer Care Center)

  • Other
    Goals of Care

    In Group 2, participants will receive the above usual standard of care plus goals of care (GOC) intervention.

    Other: Standard of Care (Goals of Care)

Interventions

  • OtherStandard of Care (Acute Cancer Care Center)

    In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.

  • OtherStandard of Care (Goals of Care)

    In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.

06

What researchers measure

Primary outcomes

  1. Quality Of Life Questionnaire

    Time frame: through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    • Ahmed Elsayem, MD,MPH · Contact · aelsayem@mdanderson.org · 713-745-9911
    • Ahmed Elsayem, MD,MPH · Principal investigator
    Recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06420206
Lead sponsor
M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
May 17, 2024
Start date
May 14, 2024
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Ahmed Elsayem, MD,MPH
Contact
aelsayem@mdanderson.org
(713) 745-9911
Ahmed Elsayem, MD,MPH
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion